Concepedia

Kapil Bahl

KB

Statistics

Publications

24

Citations

4.2K

H-Index

20

Active since

1999

Affiliations

Moderna Therapeutics (United States)(Current)

National Institutes of Health

National Institute of Allergy and Infectious Diseases

University of Massachusetts Chan Medical School

Yale University

Kapil Bahl is an author at Moderna Therapeutics (United States) specializing in immunology, infectious diseases, and vaccinology.

ORCID

Publications per year

1999–2023

24

Publications

24

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Kizzmekia S. Corbett, Darin K. Edwards, Sarah R. Leist et al. · Nature · 2020 · 1.7K citations · Full text

, , +14

Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses

Kapil Bahl, Joe J. Senn, Olga Yuzhakov et al. · Molecular Therapy · 2017 · 654 citations · Full text

, , +17

Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques

Frank Liang, Gustaf Lindgren, Ang Lin et al. · Molecular Therapy · 2017 · 400 citations · Full text

, , +17

Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection

Amy S. Espeseth, Pedro J. Cejas, Michael Citron et al. · npj Vaccines · 2020 · 186 citations · Full text

, , +17

A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques

Peng Zhang, Elisabeth Narayanan, Qingbo Liu et al. · Nature Medicine · 2021 · 165 citations

, , +14

1–5 of 24